Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) EBITDA (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of EBITDA data on record, last reported at $583.2 million in Q4 2025.

  • For Q4 2025, EBITDA rose 395.94% year-over-year to $583.2 million; the TTM value through Dec 2025 reached -$225.7 million, up 62.34%, while the annual FY2025 figure was -$1.1 billion, 88.45% down from the prior year.
  • EBITDA reached $583.2 million in Q4 2025 per RVMD's latest filing, up from -$303.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $583.2 million in Q4 2025 and bottomed at -$303.4 million in Q3 2025.
  • Average EBITDA over 5 years is -$87.2 million, with a median of -$92.3 million recorded in 2022.
  • Peak YoY movement for EBITDA: crashed 191.67% in 2023, then skyrocketed 395.94% in 2025.
  • A 5-year view of EBITDA shows it stood at -$52.9 million in 2021, then dropped by 16.62% to -$61.7 million in 2022, then plummeted by 191.67% to -$180.0 million in 2023, then fell by 9.49% to -$197.1 million in 2024, then surged by 395.94% to $583.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $583.2 million in Q4 2025, -$303.4 million in Q3 2025, and -$264.7 million in Q2 2025.